Re-defining frontline myeloma therapy: The emerging role of BCMA-directed strategies in newly diagnosed multiple myeloma
Despite significant advances in newly diagnosed multiple myeloma (NDMM), key challenges remain, from optimizing risk and frailty assessment to overcoming relapse and treatment burden. This on-demand symposium, recorded at the 12th World Congress on Controversies in Multiple Myeloma (COMy) 2026 in Paris, critically examines the biological rationale and emerging clinical evidence supporting earlier use of BCMA-targeted therapies, including bispecific antibodies, CAR-T, and ADCs, and what this could mean for future treatment strategies.
Was your question not answered live? Our experts have responded, please see the Q&A tab after clicking “Watch webcast.”
Chair – Mohamad Mohty
María-Victoria Mateos
Florent Malard
Evangelos Terpos
Wendy Bursey
- Utilize strategies to more effectively assess risk and frailty in newly diagnosed multiple myeloma (NDMM) to inform individualized treatment approaches.
- Critically appraise the biological and translational rationale for introducing BCMA-directed therapies earlier in MM treatment.
- Interpret the efficacy, safety, and future implementation challenges of BCMA-targeted therapies in newly diagnosed patient populations.
In addition to the expert faculty, Springer Healthcare IME planners and staff include Rachel Goddard and Rebecca Cox. The planning committee have no financial relationships to disclose.
All relevant financial relationships of the faculty have been mitigated.
This on-demand symposium is aimed at global (excluding US) hematologists, oncologists, specialist nurses, and all other healthcare professionals (HCPs) managing multiple myeloma.
